Italian Team Validates Preimplantation Screening Method Behind Illumina's Upcoming Commercial Test | Clinical Sequencing News | Clinical Genomics | GenomeWeb Welcome google_1369316667. Log out. | My account SEARCH Search Thursday, March 27, 2014 Italian Team Validates Preimplantation Screening Method Behind Illumina's Upcoming Commercial Test In this issue of Clinical March 26, 2014 Sequencing News By Molika Ashford Type size: Researchers from Italy's Genoma Molecular Genetics Laboratory in Rome have published a validation of an Illumina sequencing method for preimplantation genetic diagnosis and screening that they said reflects closely the methodology Email Printer-friendly version RSS Feed behind the VeriSeq commercial PGS test Illumina plans to launch later this year. The study, published online this month in the journal Fertility and Sterility, retrospectively compared the sequencing approach to established aneuploidy results from previous array-CGH testing of 68 embryos, as well as results in single cells from cultured amniotic fluids or products of conception. Italian Team Validates Preimplantation Screening Method Behind Illumina's Upcoming Commercial Test Trovagene Launches Noninvasive NGSbased Test to Monitor KRAS Mutations Cancer Dx Labs Explore NGS Gene Fusion Assays from Enzymatics, Fusion Genomics TGen Case Study Reveals Benefits of Clinical Tumor Sequencing, Complexities of Cancer According to the authors, the sequencing method, which involved paired-end sequencing on the Illumina HISeq2000 of amplification products created using BlueGnome technology, showed 100 percent sensitivity and specificity in identifying aneuploid embryos, a promising indication of its clinical validity and potential utility compared to current methods. Francesco Fiorentino, the study's first author told Clinical Sequencing News in an email that his group decided to work with Illumina to validate the method because it believed sequencing-based PGS could reduce costs and enhance precision compared to current methods, which rely on various types of microarrays. "We wanted to use Illumina's sequencing technology because of its reliability, wider experience in the NGS field compared to other technologies, [and] also because [these] NGS instruments were already available in [our] lab," Fiorentino wrote. According to Fiorentino, "from [a] technical point of view," the protocol used in his team's study is "very similar" to the protocol behind the commercial sequencing PGS test, VeriSeq, that Illumina has said it plans to launch during the second quarter of this year. Based on the results of the lab's completed validation work so far, Fiorentino said Genoma will "certainly adopt" VeriSeq after its launch. "We are very keen to introduce this technology on [a] clinical basis," he wrote, adding that the lab would consider other NGS approaches to PGS "only after being thoroughly validated and after having demonstrated similar performances and characteristics." Tristan Orpin, senior vice president of Illumina’s reproductive and genetic health business told CSN in an email that Genoma has been a customer "for a number of years and was selected to take part in the beta validation and early access of the PGS solution using NGS [while] a number of other groups around the world are also validating this application on Illumina sequencing platforms.” Apart from the Genoma lab's efforts using Illumina sequencing, other groups are also exploring alternate sequencing strategies for NGS-based preimplantation screening. GenomeWebinars PicoPLEX DNA-Seq: Single Cell Sequencing, Theory and Applications In this archived webinar, recorded Feb. 19, 2014, two speakers outline applications of Rubicon Genomics' PicoPLEX DNA-seq single cell library preparation kit. Jeramiah Smith, assistant professor of biology at the University of Kentucky, discusses the use of PicoPLEX DNA-seq for de novo sequencing of single amphibian chromosomes, while John Langmore, cofounder and chief scientific officer of Rubicon, details the use of PicoPLEX DNA-seq for aneuploidy, CNV, and STR testing of single human cancer and reproductive cells. Speakers: Jeramiah Smith, Assistant Professor of Biology, University of Kentucky; and John Langmore, Co-Founder and Chief Scientific Officer, Rubicon Genomics Sponsor: Rubicon Genomics Recording Date: 2/19/2014 Recording Time: 1 hour Young Investigator Profile Blog Reproductive Medicine Associates of New Jersey announced earlier this year that it is currently enrolling patients in a clinical validation trial of a targeted NGS strategy using the Ion Torrent PGM and a set of sequence-specific primers for preimplantation genetic testing to aid in the selection of embryos for transfer as part of in vitro fertilization. Papers of Note People on the Move Upcoming Events http://www.genomeweb.com/clinical-genomics/italian-team-validates-preimplantation-screening-method-behind-illuminas-upcomin[27/03/2014 17:54:04] Genome Technology Digital Editions Archive Tech Guide Archives Italian Team Validates Preimplantation Screening Method Behind Illumina's Upcoming Commercial Test | Clinical Sequencing News | Clinical Genomics | GenomeWeb Dagan Wells from the University of Oxford's Nuffield department of obstetrics and Xiaoliang Sunney Xie from Harvard University have also reported on single-cell sequencing techniques to improve IVF success rates. BGI has also been testing a method, published in PLoS One, for detecting copy number variants from single-cell, low-pass, whole-genome sequencing on couples undergoing IVF, and China's Berry Genomics offers a single-cell sequencing test for preimplantation genetic diagnosis called Chrosure. According to Fiorentino, though interest is growing, no group has yet published an extensive validation of NGS-based PGS. "We are hopeful that publication of our work in a full, peer-reviewed format will allow others to assess and reproduce our data and begin to assess the use of NGS for preimplantation genetic screening and perhaps other forms of preimplantation genetic testing methodologies," he wrote. According to Fiorentino and Illumina, the Genoma group's published study represents the first section of a three-phase strategy to validate the use of the Illumina method for comprehensive aneuploidy screening as a preclinical step "toward its routine use in the diagnosis of chromosomal aneuploidy on embryos." These first validation results showed that the approach was 100 percent consistent in its aneuploid embryo calls with array-CGH results using Illumina’s 24sure array, a current widely-used test originally developed by BlueGnome, which Illumina acquired in 2012. A recent survey found that oncologists have varying degrees of "genomic confidence," which affects their use of certain genetic tests. How do you think physicians' genetic knowledge can be bolstered? Medical schools should emphasize genetics and genomics. Continuing medical education in genetics and genomics should be encouraged. Guidelines for the use of such tests should be developed. Diagnostic companies should explain the benefits of their tests. All of the above The second phase of the three-part validation strategy has focused on clinical application of the NGS protocol in a prospective trial involving analysis of human embryos at blastocyst stage of development. None of the above Vote View Results Beyond this, the team is also studying pregnancy rates following transfer of screened embryos to establish that the NGS method does as well or better than current array methods in terms of its ultimate outcome in allowing successful births. "The only effective way to demonstrate its clinical usefulness is to perform a well designed and well executed [randomized controlled trial], showing actual improvements in clinical outcomes. The results of the above study will be critical when considering the use of this new technology in a clinical setting and will help to outline the potential for routine clinical use of NGS-based preimplantation embryo assessment," Fiorentino wrote. Fiorentino told CSN in a later interview that the team's followup prospective study is already complete and the group is submitting it now for publication. "The results overlapped well with the validation that has just been published," he said. "We compared [NGS again] to array CGH results using the BlueGnome 24sure array and we achieved a very high rate of pregnancy." Moving forward, Fiorentino said Genoma is also working on a study using mixes of euploid and aneuploid cells to assess the accuracy and resolution limit of the Illumina method for detecting chromosomal mosaicism. "Now that trophectoderm biopsy is becoming the preferred stage for PGS, mosaicism may represent an issue in the analysis and interpretation of the results after [chromosomal screening]. Although its significance for implantation and the developmental potential of embryos is still unclear, it is reasonable to assume that this phenomenon is likely to influence IVF success rates," he wrote. Illumina declined to comment further on when it expects to launch VeriSeq this year. Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. Related Stories NJ Reproductive Clinic to Adopt NGS for Preimplantation Genetic Testing if Validation Trial Succeeds February 12, 2014 / Clinical Sequencing News http://www.genomeweb.com/clinical-genomics/italian-team-validates-preimplantation-screening-method-behind-illuminas-upcomin[27/03/2014 17:54:04] Italian Team Validates Preimplantation Screening Method Behind Illumina's Upcoming Commercial Test | Clinical Sequencing News | Clinical Genomics | GenomeWeb UCSF Studying Exome Sequencing for Metabolic and Immune Disorders, Predicting PGx Risk in Children September 25, 2013 / Clinical Sequencing News Long-read Sequencing Offers Phasing Data for HIV Drug Resistance Mutations March 24, 2014 / GenomeWeb Daily News Illumina's Q4 Array Sales Jump 10 Percent on Consumer Genomics, BlueGnome IVF Demand February 4, 2014 / BioArray News Illumina Gains 'Early Penetration' into Clinical Markets as It Eyes More FDA Submissions January 29, 2014 / Clinical Sequencing News Science Business Funding GenomeWebinars Through an epigenome-wide The FDA Microbiology Harvard Medical School and Standardized Assays for association study, researchers have linked DNA Devices Panel of the Medical Devices Advisory Committee Columbia University have both received grants from the Personalized Immune Response Monitoring methylation at three spots in one gene to body-mass has recommended first-line use of Roche's cobas HPV National Institute of Allergy and Infectious Diseases, Sponsor: Myriad RBM index. Investigators examined the methylation test for women 25 years and older to assess their risk of totaling $12.3 million this year, to create translational Date and Time: May 15, noon ET status of nearly 480 people, finding a handful of probes cervical cancer based on the presence of clinically relevant research centers to develop molecular diagnostics GenomeWeb and Myriad RBM invite associated with BMI. The researchers confirmed three high-risk HPV DNA. If the FDA follows through on the technologies. Funded under NIAID's Centers of you to a free online presentation by Matthew Albert of the Institut Pasteur of those probes — all in intron one of the HIF3A gene recommendation, the cobas HPV test, which provides Excellence for Translational Research program, the on recent progress in personalized immune response monitoring. — in two additional cohorts. They noted, though, that methylation at these HIF3A sites was likely a consequence rather than a cause of increased BMI. genotyping information for HPV 16, 18, and 12 other high-risk HPV types, would be the first HPV test indicated for first-line screening of cervical cancer in the US. grants will provide $6.3 million to Columbia and $6 million to HMS this year. Columbia's center could receive a total of $31 million in funding over the full term of the award. Dr. Albert will share findings from the Milieu Interieur Project, a populationbased study that aims to identify the genetic and environmental determinants of immune phenotype variance and establish a path towards personalized medicine. Register here. Text Sponsorship: Visit Asuragen.com to read the #1 most downloaded article published in JMD in 2013 – Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens. Text Sponsorship: Visit GenoLogics to learn why Clarity LIMS™ is the #1 LIMS amongst lab managers and scientists for managing NGS and other genomics sample information. Text Sponsorship: Did you know that ethidium bromide is a teratogen and carcinogen? Why put yourself and the environment at risk? Midori Green DNA Gel Stain is a safe replacement for EtBr! Kick your EtBr habit & request a FREE sample of Midori Green with promo code GWMG1403. Exclusively provided by BULLDOG BIO. Text Sponsorship: ApoptosisMAP Webinar. Learn about Myriad RBM's quantitative ApoptosisMAP service and its utility in cancer research, including the ability to help identify responders to apoptosis inducers or other chemotherapeutic regimes. Access the on-demand webinar. Copyright © 2014 Genomeweb LLC. All rights reserved. About | FAQ | Subscriptions | Media Kit | Contact us | Privacy policy | My account http://www.genomeweb.com/clinical-genomics/italian-team-validates-preimplantation-screening-method-behind-illuminas-upcomin[27/03/2014 17:54:04]
© Copyright 2024 Paperzz
